Sugi Predict

Sugi Predict / Compounds / SCHEMBL1977334

SCHEMBL1977334

SCHEMBL1977334

CCCCCCCOCCCCCCCC[O]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ CES2 O00748 2/20 0.52
▸ TSHR P16473 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ CA1 P00915 6/20 0.43
▸ CA2 P00918 6/20 0.43
▸ CA9 Q16790 6/20 0.43
▸ LPAR3 Q9UBY5 3/20 0.43
▸ LPAR1 Q92633 2/20 0.43
▸ LPAR2 Q9HBW0 2/20 0.43
▸ CA12 O43570 2/20 0.43
▸ CA3 P07451 2/20 0.43
▸ CA4 P22748 2/20 0.43
▸ CA6 P23280 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9813416 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL10335490 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL2528980 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL7702021 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL2532266 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL14360432 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL7340118 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL10787974 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL4293421 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT
SCHEMBL2533547 1.00 MEN1 (0.56) MEN1THRBHTTKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205646-A2 INTERMEDIATES FOR THE MANUFACTURE OF (R)-5-[2- (5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE (INDACATEROL) Laboratorios Lesvi, S.L. (ES) 2017-08-16 — — EP disclosed
EP-2978745-B1 PROCESS FOR THE MANUFACTURE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE LESVI LABORATORIOS SL (ES) 2017-03-15 — — EP disclosed
EP-2978745-A1 PROCESS FOR THE MANUFACTURE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE Laboratorios Lesvi, S.L. (ES) 2016-02-03 — — EP disclosed
WO-2014154841-A1 PROCESS FOR THE MANUFACTURE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE LABORATORIOS LESVI, S.L. (ES) 2014-10-02 — — WO disclosed
EP-2132179-B1 PROCESS FOR PREPARING ISOMERS OF CARMOTEROL CIPLA LTD (IN) 2012-08-08 — — EP disclosed
US-8236959-B2 Process for preparing isomers of carmoterol CIPLA LIMITED (IN) 2012-08-07 — — US disclosed
EP-1613599-B8 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2011-06-22 — — EP disclosed
EP-1613599-B1 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2010-12-15 — — EP disclosed
US-20100113790-A1 Process for Preparing Isomers of Carmoterol CIPLA LIMITED (IN) 2010-05-06 — — US disclosed
EP-2132179-A1 PROCESS FOR PREPARING ISOMERS OF CARMOTEROL Cipla Limited (IN) 2009-12-16 — — EP disclosed
EP-1542980-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR Inotek Pharmaceuticals Corporation (US) 2005-06-22 — — EP disclosed
EP-1487781-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES Novartis AG (CH) 2004-12-22 — — EP disclosed
WO-2004087668-A1 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2004-10-14 — — WO disclosed
WO-2004076422-A1 PROCESS FOR PREPARING 5-‘(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST NOVARTIS AG (CH) 2004-09-10 — — WO disclosed
US-20040116423-A1 5-Aryltetrazole compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-06-17 — — US disclosed
WO-2004009563-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR INOTEK PHARMACEUTICALS CORPORATION (US) 2004-01-29 — — WO disclosed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 — — US disclosed
WO-2003076387-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2003-09-18 — — WO disclosed
EP-0357702-A1 FLUORINATED OLIGOPHENYL DERIVATIVES. MERCK PATENT GMBH (DE) 1990-03-14 — — EP disclosed
WO-1989006678-A1 FLUORINATED OLIGOPHENYL DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1989-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113790-A1 Process for Preparing Isomers of Carmoterol NR1H2, NR1H3, ADRB1 MEN1 3696/4885THRB 925/4885HTT 3891/4885
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NAT1, AADAC, IDH3A MEN1 2689/4885THRB 2033/4885HTT 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.